
zzso is the zzso zzso zzso approved by the zzso in 2011 for advanced melanoma on the basis of survival zzso Since that time, we have made significant strides in zzso this therapy: we have characterized the spectrum of zzso adverse events and learned how to mitigate them with treatment zzso discovered potential zzso of activity, and identified the potential zzso between checkpoint zzso and other therapeutic zzso Recent phase I trials have established the efficacy and safety of next-generation checkpoint agents, including zzso and zzso zzso across multiple tumor zzso Much work lies ahead in developing these next-generation checkpoint agents, testing them in zzso and determining how to integrate them into the treatment zzso of various tumor zzso 

